Peter Paul Toth, MD, PhD
January 15th, 2013
Is HDL Fool’s Gold?
Peter Paul Toth, MD, PhD
Peter P. Toth offers his perspective on recent trials of niacin, including HPS2-THRIVE and AIM-HIGH.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?